S.BIOMEDICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34,000 KRW | +2.41% |
|
-18.07% | +195.65% |
| 2023 | S.Biomedics CO., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2023 | S.Biomedics CO., LTD. has completed an IPO in the amount of KRW 13.5 billion. | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales * | - | Sales 1 * | - | Capitalization | 130B 95.96M |
|---|---|---|---|---|---|
| Net income * | - | Net income 1 * | - | EV / Sales * | - |
| Net cash position * | - 0 | Net cash position 1 * | - 0 | EV / Sales 1 * | - |
| P/E ratio * |
-
| P/E ratio 1 * |
-
| Employees | - |
| Yield * |
-
| Yield 1 * |
-
| Free-Float | 70.2% |
More Fundamentals
* Assessed data
| 1 day | +2.41% | ||
| 1 week | -18.07% | ||
| Current month | -0.29% | ||
| 1 month | -12.82% | ||
| 3 months | +251.60% | ||
| 6 months | +368.32% | ||
| Current year | +195.65% |
1 week
30 950.00
39 000.00
1 month
30 950.0049 500.00
Current year
7 800.0049 500.00
1 year
6 950.0049 500.00
3 years
6 950.0049 500.00
5 years
6 950.0049 500.00
10 years
6 950.0049 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sae-Il Kang
CEO | Chief Executive Officer | 44 | 18-03-28 |
Dong-Wook Kim
CEO | Chief Executive Officer | 63 | 19-03-30 |
Myung-Soo Cho
CTO | Chief Tech/Sci/R&D Officer | 55 | 19-03-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sae-Il Kang
CEO | Chief Executive Officer | 44 | 18-03-28 |
Dong-Wook Kim
CEO | Chief Executive Officer | 63 | 19-03-30 |
Myung-Soo Cho
CTO | Chief Tech/Sci/R&D Officer | 55 | 19-03-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 34,000 | +2.41% | 781,291 |
| 24-05-16 | 33,200 | -2.06% | 619,970 |
| 24-05-14 | 33,900 | -14.50% | 1,215,739 |
| 24-05-13 | 39,650 | -4.46% | 508,140 |
End-of-day quote Korea S.E., May 16, 2024
More quotes
S Biomedics Co Ltd is a Korea-based company primarily engaged in the manufacture and sale of biopharmaceuticals. The Company operates business through two segments. The Medical Devices segment engages in the manufacture and sale of medical devices and cosmetics. The Stem Cell Therapeutics segment is primarily engaged in the manufacture and sale of stem cell therapies. Additionally, this segment is engaged in stem cell research and development (R&D).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +195.65% | 287M | |
| -3.05% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| +59.82% | 25.73B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +5.24% | 8.79B |
- Stock Market
- Equities
- A304360 Stock
